EE156 Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure (HF) with Preserved Ejection Fraction (HFPEF) in France, Based on Emperor-Preserved Clinical Trial

Abstract

EMPEROR-Preserved was a phase III, randomized and double-blind trial comparing empagliflozin to placebo, both added to Standard of Care (SoC), in patients with HFpEF. Empagliflozin showed a 21%-reduction in combined risks of cardiovascular (CV) death or HF-hospitalization (95%CI: 0.69-0.90, p<0.001) and a 27%-reduction in total number of HF-hospitalizations (95%CI: 0.61-0.88, p<0.001). A Markov model was adapted to assess the impacts of empagliflozin+SoC vs. SoC for HFpEF in France.